Caribou Biosciences will stop work on two remaining off-the-shelf allogeneic CAR T programs and pursue strategic alternatives after failing to secure enough financing for late-stage clinical plans. The company framed the move as a response to the funding environment and regulatory/clinical execution requirements. Caribou’s shutdown underlines the capital intensity of completing late-stage development for cell therapies, particularly when manufacturing scale-up and trial readiness require sustained funding. It also shifts attention to how investors evaluate platform-driven cell therapy bets versus near-term clinical milestones. For the sector, the decision may influence deal activity around orphaned or de-risked assets and accelerate reverse-merger interest where programs can be supported with fresh capital.